Panel Discussion: From generic success to innovation leadership What’s next for Indian Pharma

Panellists Speaker in this video:
○ Mr Rajesh Kumar Chopra, Founder & CEO, RAJBIOTEC (Moderator)
○ Dr Sukhjeet Singh, CSO, Acme Formulations
○ Mr Anmol Aggarwal, Lead, R&D Strategy, Venus Remedies
○ Dr Pankaj Bhatt, AVP – Technical Operations, Piramal Consumer Healthcare
○ Mr Bhupendra Pratap Singh Chauhan, Head CQA (Formulation), Morepen Laboratories
○ Mr Bhapinder Singh Grover, Founder & CEO, BSG Pharmaconsult
○ Mr Gursharanjit Singh, GM-Operations, Gracure Pharmaceuticals

Key Highlights:
[1] India must transition from a generics leader to an innovation-driven pharmaceutical powerhouse.

[2] Stronger R&D infrastructure, funding, and policy support are essential to drive innovation.

[3] Collaboration between industry, academia, regulators, and global partners is key to successful drug development.

[4] AI, digitalisation, and smart manufacturing will improve quality, productivity, and regulatory compliance.

[5] Mid-sized companies need timely funding and strategic partnerships to commercialise innovative products.

[6] India should expand beyond generics into biosimilars, biologics, peptides, and novel therapies to increase export value.

[7] Developing specialised talent, strong IP strategies, and globally recognised brands will strengthen India’s global pharmaceutical leadership.

The post Panel Discussion: From generic success to innovation leadership What’s next for Indian Pharma appeared first on Express Pharma.